NCT06827080View on ClinicalTrials.gov

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Metastatic Castration-resistant Prostate Cancer, MCRPCCancer
Interventions
DRUG

30 mCi NYMO32

The initial dose is set at 30 mCi.

DRUG

50 mCi NYMO32

The dose will be escalated to 50 mCi.

DRUG

80 mCi NYMO32

The dose will be escalated to 80 mCi.

DRUG

130 mCi NYMO32

The dose will be escalated to 130 mCi.

DRUG

200 mCi NYMO32

The maximum dose is set at 200 mCi.

All Listed Sponsors
lead

Zhengguo Chen

OTHER